Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

Download this page as JSON

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04636814/registered

API reference For AI assistants

List	Outcome	Time frame	Description
Primary	The number of moderate and severe exacerbations occurring during the planned 52-week treatment period.	Up to 52 weeks	Moderate or severe exacerbation is defined by symptomatic worsening of COPD: * Moderate : requiring use of systemic corticosteroids (oral/IV/IM corticosteroids), and/or use of antibiotics * Severe : requiring hospitalisation or resulting in death
Secondary	The time to first moderate or severe exacerbation.	Up to 52 weeks	The time to first moderate or severe exacerbation.
Secondary	The annual rate of severe exacerbations.	Up to 52 weeks	The annual rate of severe exacerbations.
Secondary	The time to first severe exacerbation.	Up to 52 weeks	The time to first severe exacerbation.
Secondary	The number of all on-treatment severe exacerbations.	Up to 52 weeks	The number of all on-treatment severe exacerbations.
Secondary	The number of all on-treatment exacerbations requiring systemic corticosteroids.	Up to 52 weeks	The number of all on-treatment exacerbations requiring systemic corticosteroids.
Secondary	Change from baseline (pre-dose Visit 2) in pre-dose FEV1, at week 52.	At week 52	Change from baseline (pre-dose Visit 2) in pre-dose FEV1, at week 52.
Secondary	Change from baseline in Saint Georges Respiratory Questionnaire (SGRQ) total and domain scores at week 52.	At week 52	Change from baseline in Saint Georges Respiratory Questionnaire (SGRQ) total and domain scores at week 52.
Secondary	Saint Georges Respiratory Questionnaire response (SGRQ) (change from baseline SGRQ total score ≤ -4) at week 52.	At week 52	Saint Georges Respiratory Questionnaire response (SGRQ) (change from baseline SGRQ total score ≤ -4) at week 52.
Secondary	Change from baseline to last inter-visit period (week 40-52) in EXACT-Respiratory Symptoms (E-RS) Total and subscale scores.	Up to 52 weeks	Change from baseline to last inter-visit period (week 40-52) in EXACT-Respiratory Symptoms (E-RS) Total and subscale scores.
Secondary	E-RS response (change from baseline E-RS Total score ≤ -2) at week 52.	At week 52	E-RS response (change from baseline E-RS Total score ≤ -2) at week 52.
Secondary	Change from baseline to last inter-visit period (week 40-52) in the percentage of days without intake of rescue medication and in the average rescue medication use (number of puffs).	Up to 52 weeks	Change from baseline to last inter-visit period (week 40-52) in the percentage of days
Secondary	Time to study medication discontinuation for any reason.	Up to 52 weeks	Time to study medication discontinuation for any reason.
Secondary	Time to moderate or severe exacerbation or study medication discontinuation due to any adverse event, lack of efficacy or death (composite endpoint) and time to study medication discontinuation component.	Up to 52 weeks	Time to moderate or severe exacerbation or study medication discontinuation due to any adverse event, lack of efficacy or death (composite endpoint) and time to study medication discontinuation component.
Secondary	Time to first moderate/severe exacerbation or study medication discontinuation due to any class-related AE, lack of efficacy, or death (composite endpoint) and time to study medication discontinuation component.	Up to 52 weeks	Time to first moderate/severe exacerbation or study medication discontinuation due to any class-related AE, lack of efficacy, or death (composite endpoint) and time to study medication discontinuation component.
Secondary	Key Secondary Variable: Change from baseline in SGRQ Total score at week 52	At week 52	Key Secondary Variable: Change from baseline in SGRQ Total score at week 52